Trial Profile
A Phase 2 Study of Ibrutinib and Blinatumomab in Relapsed and Refractory B-Cell Acute Lymphoblastic Leukemia
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 30 Nov 2023
Price :
$35
*
At a glance
- Drugs Blinatumomab (Primary) ; Ibrutinib (Primary)
- Indications Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Therapeutic Use
- 27 Nov 2023 Planned End Date changed from 1 Mar 2024 to 1 Sep 2024.
- 27 Nov 2023 Planned primary completion date changed from 1 Sep 2023 to 1 Mar 2024.
- 02 Feb 2023 Planned End Date changed from 1 Jan 2023 to 1 Mar 2024.